About Boris Reznik
Boris Reznik is chairman and CEO of Immorta Bio, which develops cell therapies for cancer, organ failure and age-related disease.
Over four decades, Reznik founded technology companies, managed Inc. 500 businesses and led programs that won drug and biologic approvals. He worked with Fortune 500 and emerging companies as clients and partners. He also invested in technology businesses and participated in merger-and-acquisition transactions ranging from millions to billions of dollars. He previously chaired Venvalo Group, a venture value firm, and BioRASI, a contract research organization. At BioRASI, he guided treatments from initial regulatory filings through drug approvals. Reznik holds patents and has authored numerous publications. He earned an associate degree in mathematics and a master's in mechanical engineering. He also earned a doctorate from the Soviet Academy of Sciences.
Experience
This experience comes from official bios and from SEC filings. For roles taken from filings, the years are when the filings name Boris Reznik in the role, so the role may have started earlier or lasted longer.
